Privia Health Group, Inc. operates as a national physician-enablement company in the United States.
$24.42+2.00%
报价 2026-11-06
市值
$3.12B
EV
$2.68B
PE (TTM)
87.5x
预期 PE (FY2026)
94.9x
52 周区间距高点 -13.1%
$19.10$28.10
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 0.37 → 0.42（1.1x） | 58.6 |
| FY+32028-12 | 1.2x | 0.37 → 0.57（1.5x） | 42.7 |
毛利率 11% · TTM 收入 $2435M · 基数 EPS 0.37（调整后）
电话会信号
辅助标签Q3 20262026-11-05
上调指引
指引 上调
信心 5
分析师 4
“We expect to reach 6,000 clinicians by year-end and adjusted EBITDA growth of 23.9% at the midpoint.”
原文引用（1）
- 上调指引：we are raising our 2026 outlook above the high end of our initial guidance for all key financial metrics
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
L2 2026-07-02全文 ↓尚未生成 L3 估值，没有三情景目标价。去生成估值 →
L2 报告格式无法提取要点，请看全文。
历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PRVAPrivia Health Group, Inc. | $3.12B | +2.0% | +17.1% | 21% | 87.5x | 36.0x | 28.9x | |
| LIVNLivaNova PLC | $4.96B | -1.3% | +10.4% | 67.4% | 25.1x | 22.4x | 38.4x | GARP |
| TVTXTravere Therapeutics, Inc. | $4.76B | +1.5% | +40.1% | 94.4% | – | 4103.2x | 705.8x | |
| HTFLHeartflow, Inc. Common Stock | $4.56B | +0.9% | +43.4% | 83% | – | – | – | 高增长 |
| ICUIICU Medical, Inc. | $4.3B | +2.7% | -0.8% | 36.4% | 90.1x | 20.0x | 52.4x | |
| NVSTEnvista Holdings Corp | $4.04B | +0.9% | +8.7% | 57.9% | 6.4x | 5.2x | 17.9x | Cheap |
| ARQTArcutis Biotherapeutics, Inc. | $3.21B | -5.4% | +37.9% | 91.1% | 144.4x | 94.1x | 102.4x | |
| PBHPrestige Consumer Healthcare Inc. | $2.04B | -3.0% | +17.9% | 50% | 12.4x | 10.0x | 9.1x | GARP |
| SUPNSupernus Pharmaceuticals, Inc. | $1.52B | -2.2% | +25.9% | 85.7% | 7.1x | 3.0x | 49.1x | Cheap GARP |
| 同行中位数 | – | – | +21.9% | 75.2% | 18.8x | 20.0x | 49.1x |
研究全文
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $657M | $632.6M | $603.8M | $541.2M | $580.4M | $521.2M | $480.1M | $460.9M |
| Gross Margin | 21% | 1.9% | 9.4% | 9.2% | 10.5% | 9.1% | 9.5% | 10.4% |
| Operating Margin | 3.1% | 1.9% | 1.2% | 2.1% | 2.5% | 0.6% | 1.1% | 1.1% |
| Net Income | $13.5M | $9M | $3.1M | $9.2M | $6.9M | $2.7M | $4.2M | $4.4M |
| Diluted EPS | 0.1 | 0.07 | 0.02 | 0.07 | 0.05 | 0.02 | 0.03 | 0.03 |
| Operating Cash Flow | $28.9M | $1.1M | $-49.5M | $127.5M | $52M | $8M | $-24.1M | $74.8M |